Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis
NCT01055756 · Azidus Brasil · PHASE3 · withdrawn · last registry update 2022-10-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Azidus Brasil |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HRH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-26Results posted on the registry: National Cancer Institute (NCI), Durvalumab + Vicineum (NCT03258593)
- 2023-10-16Also stopped (withdrawn): Larkin Community Hospital, CPM + Placebo (NCT04790487)
- 2023-08-23Also stopped (withdrawn): University of Nebraska, AGEE cream + 1% Steroid Cream (NCT00988988)
- 2023-07-25Results posted on the registry: GlaxoSmithKline, Daprodustat + rhEPO (NCT03457701)
- 2023-07-14Phase 3 first posted: Emory University, Cetirizine + Famotidine (NCT05946551)
- 2023-06-02Phase 3 first posted: Dr. Ferrer BioPharma, Chlorpheniramine Maleate 0.4% Nasal Spray + Placebo (NCT05886829)
- 2023-04-18Phase 3 first posted: Guy Boeckxstaens, Ebastine + Duspatalin (NCT05815602)
- 2022-09-15Results posted on the registry: KeraNetics, LLC, Histamine + Saline (0.9% NaCl) (NCT04058054)
- 2022-07-14Phase 3 first posted: Harmony Biosciences Management, Inc., Pitolisant (NCT05458128)
- 2022-07-12Results posted on the registry: Genzyme, a Sanofi Company, Alemtuzumab GZ402673 + Glatiramer acetate (NCT03368664)
- 2022-07-08Phase 3 first posted: Dr. Ferrer BioPharma, Chlorpheniramine Maleate 1% Nasal Spray + Placebo (NCT05449405)
- 2022-05-05Results posted on the registry: Inmunotek S.L., 10 HEP/mL Betula verrucosa allergen extract + 25 HEP/mL Betula verrucosa allergen extract (NCT02527187)
- 2022-04-20Results posted on the registry: Institut Bergonié, bevacizumab + fluorouracil (NCT00467142)
- 2022-03-11Phase 3 first posted: Singapore Chung Hwa Medical Institution, a drug against HRH1 (NCT05275933)
- 2022-03-11Phase 3 first posted: Universitas Indonesia, Pharmacology treatment (NCT05276336)
- 2022-02-17Phase 3 first posted: Cairo University, Olanzapine 5 MG + Placebo (NCT05243251)
- 2022-02-03Phase 3 first posted: Citrine Medicine Limited, Pitolisant + Placebo oral tablet (NCT05223166)
- 2021-12-14Phase 3 first posted: Harmony Biosciences Management, Inc., Open-label Pitolisant + Double-blind Placebo (NCT05156047)
- 2021-11-30Phase 3 first posted: Centre Hospitalier Universitaire de Saint Etienne, Rituximab infusion + Placebo infusion (NCT05136976)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision